BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu W, He Y, Feng X, Ye S, Wang H, Tan W, Yu C, Hu J, Zheng R, Zhou Y. MicroRNA-206 is involved in the pathogenesis of ulcerative colitis via regulation of adenosine A3 receptor. Oncotarget 2017;8:705-21. [PMID: 27893428 DOI: 10.18632/oncotarget.13525] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Chen F, Wang S, Wei Y, Wu J, Huang G, Chen J, Shi J, Xia J. Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone. Biomedicine & Pharmacotherapy 2018;103:1092-100. [DOI: 10.1016/j.biopha.2018.04.100] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
2 Fu R, Yang P, Amin S, Li Z. A novel miR-206/hnRNPA1/PKM2 axis reshapes the Warburg effect to suppress colon cancer growth. Biochem Biophys Res Commun 2020;531:465-71. [PMID: 32800545 DOI: 10.1016/j.bbrc.2020.08.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
3 Luo Y, Yu MH, Yan YR, Zhou Y, Qin SL, Huang YZ, Qin J, Zhong M. Rab27A promotes cellular apoptosis and ROS production by regulating the miRNA-124-3p/STAT3/RelA signalling pathway in ulcerative colitis. J Cell Mol Med 2020;24:11330-42. [PMID: 32815642 DOI: 10.1111/jcmm.15726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Burnstock G. Purinergic Signalling: Therapeutic Developments. Front Pharmacol 2017;8:661. [PMID: 28993732 DOI: 10.3389/fphar.2017.00661] [Cited by in Crossref: 170] [Cited by in F6Publishing: 164] [Article Influence: 34.0] [Reference Citation Analysis]
5 Tili E, Michaille JJ, Piurowski V, Rigot B, Croce CM. MicroRNAs in intestinal barrier function, inflammatory bowel disease and related cancers-their effects and therapeutic potentials. Curr Opin Pharmacol 2017;37:142-50. [PMID: 29154194 DOI: 10.1016/j.coph.2017.10.010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
6 Burnstock G, Jacobson KA, Christofi FL. Purinergic drug targets for gastrointestinal disorders. Curr Opin Pharmacol 2017;37:131-41. [PMID: 29149731 DOI: 10.1016/j.coph.2017.10.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
7 Burnstock G. The therapeutic potential of purinergic signalling. Biochemical Pharmacology 2018;151:157-65. [DOI: 10.1016/j.bcp.2017.07.016] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 17.5] [Reference Citation Analysis]
8 Nakada N, Mikami T, Horie K, Nagashio R, Sakurai Y, Sanoyama I, Yoshida T, Sada M, Kobayashi K, Sato Y, Okayasu I, Murakumo Y. Expression of CA2 and CA9 carbonic anhydrases in ulcerative colitis and ulcerative colitis-associated colorectal cancer. Pathol Int. 2020;70:523-532. [PMID: 32410301 DOI: 10.1111/pin.12949] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Minacapelli CD, Bajpai M, Geng X, Van Gurp J, Poplin E, Amenta PS, Brant SR, Das KM. miR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis. Inflamm Bowel Dis 2019;25:78-84. [PMID: 30204869 DOI: 10.1093/ibd/izy279] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Guo J, Yang P, Li YF, Tang JF, He ZX, Yu SG, Yin HY. MicroRNA: Crucial modulator in purinergic signalling involved diseases. Purinergic Signal 2022. [PMID: 35106737 DOI: 10.1007/s11302-022-09840-y] [Reference Citation Analysis]
11 Chua FY, Adams BD. Androgen receptor and miR-206 regulation in prostate cancer. Transcription 2017;8:313-27. [PMID: 28598253 DOI: 10.1080/21541264.2017.1322668] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
12 Ren TH, Lv MM, An XM, Leung WK, Seto WK. Activation of adenosine A3 receptor inhibits inflammatory cytokine production in colonic mucosa of patients with ulcerative colitis by down-regulating the nuclear factor-kappa B signaling. J Dig Dis 2020;21:38-45. [PMID: 31714673 DOI: 10.1111/1751-2980.12831] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
13 Dal Ben D, Antonioli L, Lambertucci C, Spinaci A, Fornai M, D'Antongiovanni V, Pellegrini C, Blandizzi C, Volpini R. Approaches for designing and discovering purinergic drugs for gastrointestinal diseases. Expert Opin Drug Discov 2020;15:687-703. [PMID: 32228110 DOI: 10.1080/17460441.2020.1743673] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Li X, Sun L, Chen L, Xu Y, Kong X. Upregulation of microRNA-219-5p relieves ulcerative colitis through balancing the differentiation of Treg/Th17 cells. Eur J Gastroenterol Hepatol 2020;32:813-20. [PMID: 32175983 DOI: 10.1097/MEG.0000000000001712] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Antonioli L, Blandizzi C, Pacher P, Haskó G. The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases. Pharmacol Rev 2019;71:345-82. [PMID: 31235653 DOI: 10.1124/pr.117.014878] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 17.7] [Reference Citation Analysis]
16 Liu S, Zhang S, Lv X, Lu J, Ren C, Zeng Z, Zheng L, Zhou X, Fu H, Zhou D, Chen Y. Limonin ameliorates ulcerative colitis by regulating STAT3/miR-214 signaling pathway. Int Immunopharmacol. 2019;75:105768. [PMID: 31382166 DOI: 10.1016/j.intimp.2019.105768] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
17 Zhou J, Liu J, Gao Y, Shen L, Li S, Chen S. miRNA-Based Potential Biomarkers and New Molecular Insights in Ulcerative Colitis. Front Pharmacol 2021;12:707776. [PMID: 34305614 DOI: 10.3389/fphar.2021.707776] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Ghafouri-fard S, Eghtedarian R, Taheri M. The crucial role of non-coding RNAs in the pathophysiology of inflammatory bowel disease. Biomedicine & Pharmacotherapy 2020;129:110507. [DOI: 10.1016/j.biopha.2020.110507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Antonioli L, Fornai M, Pellegrini C, Bertani L, Nemeth ZH, Blandizzi C. Inflammatory Bowel Diseases: It's Time for the Adenosine System. Front Immunol 2020;11:1310. [PMID: 32849492 DOI: 10.3389/fimmu.2020.01310] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Merighi S, Gessi S, Borea PA. Adenosine Receptors: Structure, Distribution, and Signal Transduction. In: Borea PA, Varani K, Gessi S, Merighi S, Vincenzi F, editors. The Adenosine Receptors. Cham: Springer International Publishing; 2018. pp. 33-57. [DOI: 10.1007/978-3-319-90808-3_3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
21 Gottesman-Katz L, Latorre R, Vanner S, Schmidt BL, Bunnett NW. Targeting G protein-coupled receptors for the treatment of chronic pain in the digestive system. Gut 2021;70:970-81. [PMID: 33272979 DOI: 10.1136/gutjnl-2020-321193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 D'Antongiovanni V, Fornai M, Pellegrini C, Benvenuti L, Blandizzi C, Antonioli L. The Adenosine System at the Crossroads of Intestinal Inflammation and Neoplasia. Int J Mol Sci 2020;21:E5089. [PMID: 32708507 DOI: 10.3390/ijms21145089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 Buccioni M, Dal Ben D, Lambertucci C, Martí Navia A, Ricciutelli M, Spinaci A, Volpini R, Marucci G. New sensible method to quantize the intestinal absorption of receptor ligands. Bioorg Med Chem 2019;27:3328-33. [PMID: 31230970 DOI: 10.1016/j.bmc.2019.06.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Jacobson KA, Merighi S, Varani K, Borea PA, Baraldi S, Aghazadeh Tabrizi M, Romagnoli R, Baraldi PG, Ciancetta A, Tosh DK, Gao ZG, Gessi S. A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy. Med Res Rev 2018;38:1031-72. [PMID: 28682469 DOI: 10.1002/med.21456] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 13.4] [Reference Citation Analysis]
25 Choudhury H, Chellappan DK, Sengupta P, Pandey M, Gorain B. Adenosine Receptors in Modulation of Central Nervous System Disorders. Curr Pharm Des 2019;25:2808-27. [PMID: 31309883 DOI: 10.2174/1381612825666190712181955] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
26 Tian Y, Cui L, Lin C, Wang Y, Liu Z, Miao X. LncRNA CDKN2B-AS1 relieved inflammation of ulcerative colitis via sponging miR-16 and miR-195. Int Immunopharmacol 2020;88:106970. [PMID: 33182065 DOI: 10.1016/j.intimp.2020.106970] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
27 Bahreyni A, Samani SS, Khazaei M, Ryzhikov M, Avan A, Hassanian SM. Therapeutic potentials of adenosine receptors agonists and antagonists in colitis; Current status and perspectives. J Cell Physiol 2018;233:2733-40. [DOI: 10.1002/jcp.26073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
28 Soroosh A, Koutsioumpa M, Pothoulakis C, Iliopoulos D. Functional role and therapeutic targeting of microRNAs in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2018;314:G256-62. [PMID: 29146677 DOI: 10.1152/ajpgi.00268.2017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]